Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman, MD, will present at BIO-Europe Spring 2026 in Lisbon on March 24, 2026, from 1:30-1:45 p.m. WET in the Presentation Theatre A. The presentation will cover the company’s CNS and immunology programs and marketed products.
On the day this news was published, TNXP gained 11.13%, reflecting a significant positive market reaction.
Argus tracked a peak move of +7.7% during that session.
Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility.
This price movement added approximately $22M to the company's valuation, bringing the market cap to $216.36M at that time.
The stock surged +11.1% in the session following this news. A strong positive reaction aligns with T...
Analysis
The stock surged +11.1% in the session following this news. A strong positive reaction aligns with Tonix’s pattern of generally constructive responses to visibility and data milestones, as seen around recent TONMYA updates with mostly aligned price moves. However, the stock still traded 79.72% below its 52-week high and below the 200-day MA of 25.57, suggesting prior weakness. An active S-3/A shelf and the company’s ongoing capital needs, as reflected in recent filings, remained factors investors monitored when assessing durability.
Announcement of TONMYA poster on patient-centered outcomes at AAPM PainConnect.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent TNXP news has generally seen modest positive price alignment, with one notable divergence on favorable pharmacokinetic data.
Recent Company History
Over the past weeks, Tonix has highlighted commercialization and clinical progress for TONMYA, including Phase 3 data presentations and pharmacokinetic publications, plus 2025 earnings showing net product revenue of $13.1M. Most of these updates led to small positive moves, though the March 5 pharmacokinetic publication coincided with a -1.97% reaction. Today’s BIO-Europe Spring 2026 presentation fits into this pattern of ongoing visibility-building around TONMYA and the broader CNS portfolio.
Key Terms
sublingual, fibromyalgia, major depressive disorder, acute stress disorder, +4 more
8 terms
sublingualmedical
"cyclobenzaprine HCl sublingual tablets 2.8 mg"
Sublingual describes a way to take a drug or supplement by placing it under the tongue so active ingredients are absorbed through the thin tissue there directly into the bloodstream. Like taking a shortcut compared with swallowing a pill, this can produce faster effects, simpler dosing and sometimes more predictable delivery. Investors watch for sublingual formulations because they can affect a product’s market appeal, regulatory pathway, pricing and competitive positioning.
fibromyalgiamedical
"first new treatment for fibromyalgia in adults in more than 15 years"
Fibromyalgia is a long-term condition that causes widespread body pain, extreme tiredness, and problems with sleep, memory and mood; people often feel unusually sensitive to normal touch or pressure, and symptoms can fluctuate from day to day. It matters to investors because it affects workforce productivity, healthcare spending, and demand for treatments—so advances in diagnostics, drugs, or care delivery can change market size and company prospects, much like a fuel problem that reduces a car’s performance and reliability.
major depressive disordermedical
"Phase 2 clinical trials to evaluate its potential in major depressive disorder"
A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.
acute stress disordermedical
"Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder"
Acute stress disorder is a short-term mental health reaction that can occur after a traumatic event, causing intense anxiety, flashbacks, sleep problems, and difficulty functioning for days to weeks. Think of it as an alarm system that stays stuck on after a scare; it matters to investors because it can drive demand for medical treatments and mental health services, influence insurance claims and workplace productivity, and affect regulatory or legal risks for companies.
prader-willi syndromemedical
"TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome"
A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.
monoclonal antibodymedical
"immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
cd40 ligand inhibitormedical
"TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection"
A CD40 ligand inhibitor is a drug that blocks the CD40 ligand, a protein used by immune cells to send activation and inflammatory signals; think of it as turning down an alarm bell that rallies the immune system. Investors care because these drugs aim to treat autoimmune diseases, transplant rejection or inflammatory conditions, so their clinical trial results, safety profile and regulatory approval prospects directly affect a company’s future revenue potential and development risk.
prophylaxismedical
"TNX-4800 for Lyme disease prophylaxis"
Prophylaxis is a medical prevention strategy — a drug, vaccine, device, or procedure given to stop a disease or condition before it starts. For investors, prophylactic products matter because they can create steady, large markets and reduce long‑term healthcare costs; regulatory approval or broader adoption can change demand forecasts much like a new safety feature that becomes standard across an entire industry.
BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth Lederman, MD, Chief Executive Officer, will deliver a company presentation at BIO-Europe Spring 2026, being held March 23-25, 2026, in Lisbon, Portugal.
Company Presentation Details
Date and Time: Tuesday, March 24, 2026, 1:30-1:45 p.m. WET Location: Presentation Theatre A Presenter: Seth Lederman, MD, Chief Executive Officer
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals* is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.
*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
When and where will Tonix Pharmaceuticals (TNXP) present at BIO-Europe Spring 2026?
Tonix will present on March 24, 2026, 1:30–1:45 p.m. WET in Presentation Theatre A. According to Tonix Pharmaceuticals, CEO Seth Lederman, MD, will deliver the company presentation outlining its CNS and immunology portfolio.
What topics will Tonix (TNXP) likely cover in its BIO-Europe Spring 2026 presentation?
The presentation will focus on Tonix’s CNS and immunology pipeline and marketed products. According to Tonix Pharmaceuticals, topics include TONMYA, acute migraine products, TNX-2900, and immunology candidates like TNX-4800 and TNX-1500.
How can investors access Tonix Pharmaceuticals (TNXP) presentation materials or webcast from BIO-Europe Spring 2026?
Investors should check Tonix’s investor relations pages and social channels for access details. According to Tonix Pharmaceuticals, additional information and materials will be available on the company website and its LinkedIn and X accounts.
Does Tonix (TNXP) plan to discuss TONMYA clinical programs at BIO-Europe Spring 2026?
Yes, TONMYA’s development is part of the company’s CNS agenda and is expected to be discussed. According to Tonix Pharmaceuticals, TONMYA is being investigated in Phase 2 trials for major depressive disorder and acute stress disorder.
Will Tonix (TNXP) describe commercialized products like Zembrace Symtouch and Tosymra at the presentation?
Tonix is expected to highlight its commercial CNS infrastructure and marketed products. According to Tonix Pharmaceuticals, Zembrace Symtouch and Tosymra are part of the company’s marketed acute migraine portfolio supporting commercial operations.
Who is the presenter for Tonix Pharmaceuticals (TNXP) at BIO-Europe Spring 2026 and what is his role?
The presenter is Seth Lederman, MD, who serves as CEO of Tonix Pharmaceuticals. According to Tonix Pharmaceuticals, he will deliver the company presentation at the BIO-Europe Spring conference in Lisbon.
